Stockholders’ Equity - Narrative (Details) $ / shares in Units, $ in Thousands				3 Months Ended				9 Months Ended
	Jul. 10, 2023 USD ($) $ / shares shares	Jun. 16, 2022 USD ($) shares	Apr. 06, 2022 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2024 shares	Sep. 30, 2023 shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Jan. 02, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares	Apr. 08, 2022 USD ($)
Class of Stock [Line Items]
Stock issuance costs								$ 0	$ 43
Preferred shares, shares authorized (in shares) | shares				2,000,000				2,000,000			2,000,000
Preferred shares, par value (in dollars per share) | $ / shares				$ 0.0001				$ 0.0001			$ 0.0001
Preferred shares, shares issued (in shares) | shares				15,000				15,000			15,000
Preferred shares, shares outstanding (in shares) | shares				15,000				15,000			15,000
Term loan | Term loan
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares) | shares										191,096
Exercise price of warrant (in dollars per share) | $ / shares										$ 1.83
Fair value of warrant										$ 200
PIPE Purchase Agreement Pre-Funded Warrant
Class of Stock [Line Items]
Warrants exercised (in shares) | shares				0			1,793,000	0	6,300,000
Armistice Warrant Agreement
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares) | shares	9,900,990
Exercise price of warrant (in dollars per share) | $ / shares	$ 1.39
Proceeds from Issuance of Common Stock in connection with exercise of Prior Warrant and Pre-Funded Warrants	$ 13,800
Armistice Reload Warrant Agreement
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares) | shares	3,750,000
Exercise price of warrant (in dollars per share) | $ / shares	$ 5.13
Warrant expiration period	54 months
Ownership limitation percentage	0.0999
At-the-Market Offering | COMMON STOCK
Class of Stock [Line Items]
Issuance of common stock (in shares) | shares				1,282,546	1,350,169	358,210		2,990,925
Series X Convertible Preferred Stock
Class of Stock [Line Items]
Interest rate percentage			1.00%
Common stock trading price (in dollars per share) | $ / shares			$ 22.00
Common stock trading period			30 days
Accreted amount				$ 300				$ 300
Conversion price (in dollars per share) | $ / shares			$ 11.00
Convertible preferred stock (in shares)			91
Outstanding common stock, percentage			9.90%
Outstanding common stock, not to exceed, percentage			19.90%
Percentage of investment owned			50.00%
Maximum working capital line			$ 5,000
Consideration received			15,000
Stock issuance costs			100
Proceeds from sale of equity, net			14,900
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock		$ 7,500	7,500
Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Private Placement
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized			$ 15,000
Common stock trading price (in dollars per share) | $ / shares			$ 1,000
Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Private Placement | Share Issuance, Tranche One
Class of Stock [Line Items]
Number of shares issued (in shares) | shares		7,500	7,500
Cantor Fitzgerald & Co | At-the-Market Offering
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized				$ 4,500				4,500				$ 12,200
Consideration received								$ 6,400